Health
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
WILMINGTON, Del., May 01, 2026--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GV
About this update from Incyte Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":214,"url":"https://media.zenfs.com/en/business-wire.com/1440d1e90fa0081f6c5d132f0ace09ad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IJkIZ1IM0sxmqWIYo9TDyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyOA--/https://media.zenfs.com/en/business-wire.com/1440d1e90fa0081f6c5d132f0ace09ad","width":480,"height":214}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/f9d7706a27cf0f6083c47b4eb49f5321"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bK1mUU396VfatIEW02QunA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/business-wire.com/f9d7706a27cf0f6083c47b4eb49f5321","width":480,"height":480}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":268,"url":"https://media.zenfs.com/en/business-wire.com/cd91169d5e97fdb2bf767c2a62899c2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/H4nx2VgTupheK9ZthB_o7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzNg--/https://media.zenfs.com/en/business-wire.com/cd91169d5e97fdb2bf767c2a62899c2b","width":480,"height":268}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":349,"url":"https://media.zenfs.com/en/business-wire.com/cd8e22af46cbfaab2f26d9dc5e354793"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oXnrBWMB7MyZwFbjdOZg0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY5OA--/https://media.zenfs.com/en/business-wire.com/cd8e22af46cbfaab2f26d9dc5e354793","width":480,"height":349}}},{"type":"list","items":[{"val":[{"type":"text","content":"Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi® (ruxolitinib)","length":93,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi","length":104,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Jakafi XR will be available for...